Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In a phase 1 trial, JX-594 injection into hepatocellular carcinoma (HCC)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Heo, Jeong, Breitbach, Caroline J, Moon, Anne, Kim, Chang Won, Patt, Rick, Kim, Mi Kyung, Lee, Yu Kyung, Oh, Sung Yong, Woo, Hyun Young, Parato, Kelley, Rintoul, Julia, Falls, Theresa, Hickman, Theresa, Rhee, Byung-Geon, Bell, John C, Kirn, David H, Hwang, Tae-Ho
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3129795/
https://ncbi.nlm.nih.gov/pubmed/21427706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2011.39
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars